心力衰竭相关孤儿型G蛋白偶联受体的研究进展

Advances in Orphan G-Protein-Coupled Receptors Associated with Heart Failure

G蛋白偶联受体是已知的浆膜受体中最大的家族,介导并参与多种细胞外信号的转导。这些包括神经递质、气味和光信号。由于它们广泛表达于人体的各种器官和组织中,可作为治疗各种疾病的药物靶点。其中,一些G蛋白偶联受体的内源性配体尚未被鉴定出来,称为孤儿G蛋白偶联受体。它们具有多种生理功能,具有治疗不同疾病的潜力。心力衰竭是一种由心脏血液循环系统的结构和功能损害引起的全身性疾病。虽然新药物的引进和应用大大降低了心力衰竭的死亡率和再住院率,但它仍然是发病率和死亡率的一个主要原因。因此,迫切需要开发新的药物来改善心力衰竭的症状和预后。近年来,研究发现许多孤儿g蛋白偶联受体可通过不同途径参与心力衰竭的发生发展,作为心力衰竭新的治疗靶点越来越受到关注。在探索GPR22、GPR35、GPR37L1在心力衰竭中的作用时,我们发现了更有效的新药物靶点,并阐明了新的治疗策略。

G-protein-coupled receptors are the largest family of plasma membrane receptors known to mediate and participate in the transduction of a variety of extracellular signals. These include neurotransmitters, odors, and light signals. As they are widely expressed in various organs and tissues of the body, they can be used as drug targets to treat various diseases. Among them, the endogenous ligands of some G-protein-coupled receptors have not been identified and are known as orphan G-protein-coupled receptors. They have a variety of physiological functions and the potential to be used to treat different diseases. Heart failure is a systemic disease caused by the structural and functional impairment of the cardiac blood circulatory system. While the introduction and application of new drugs have significantly reduced the mortality and re-hospitalization rates of heart failure, it remains a major cause of morbidity and mortality. Subsequently, there is an urgent need to develop new drugs to improve the symptoms and prognosis of heart failure. In recent years, studies have found that many orphan G-protein-coupled receptors can participate in the occurrence and development of heart failure through different pathways and have received increasing attention as new therapeutic targets for heart failure. In exploring the role of GPR22, GPR35, GPR37L1 in heart failure, we found more effective new drug targets and shed light on novel strategies for treatment.